Company intelligence / Profile preview

InnaVirVax

Evry, Île-de-France, Francepmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

VAC‑3S, a therapeutic vaccine for HIV, has reached Phase IIa clinical development. The company’s approach targets the preservation of CD4+ T cells by modulating innate immunity. Preclinical studies have shown efficacy in non-human primates, and first-in-human studies have been authorized. Other pipeline assets include an AIDS prognostic test and an innovative cancer biotherapy.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: VaccineBiologicImmunotherapy
Industry: Biotech

Drug pipeline

2 assets

VAC-3S

1 more asset in the full pipeline.

Request access →

Partnerships

FIT Biotech Oy – collaboration to combine proprietary immunotherapies for a functional cure of HIV using both companies’ vaccine technologies.

Beyond the preview

Go deeper on InnaVirVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnaVirVax.

Explore the full profile